VOLUME 4 (2013)
View Archive »
About The Cover
Visualizing Two-Compartment Tumor Metabolism, with Metabolic Marker Proteins: MCT4 and TOMM20. Human breast cancer samples (from primary tumors or lymph node metastases) were immuno-stained with antibodies directed against MCT4 (shown in RED) and TOMM20 (shown in BROWN). Image was digitaly enhanced for the cover of Oncotarget. See
Sotgia et al.
Table of Contents
Editorial
|
| Adoptive Tcell therapy to treat liver cancer: Is the liver microenvironment key |
|
https://doi.org/10.18632/oncotarget.1179
|
| 1117-1118 |
|
| Cancer detection using wholegenome sequencing of cell free DNA |
|
https://doi.org/10.18632/oncotarget.1183
|
| 1119-1120 |
|
| Regulation of Mdm2 mRNA Stability by RNAbinding Protein RNPC1 |
|
https://doi.org/10.18632/oncotarget.1185
|
| 1121-1122 |
|
| Restoring hemidesmosomes to prevent cancer cell invasiveness |
|
https://doi.org/10.18632/oncotarget.1196
|
| 1123-1124 |
|
| ATM is activated in blood monocytes after tumor radiation |
|
https://doi.org/10.18632/oncotarget.1286
|
| 1125 |
Editorial Broadcast
|
| A new Achilles Heel in breast cancer |
|
https://doi.org/10.18632/oncotarget.1178
|
| 1126-1127 |
|
| Overcoming treatment resistance in acute promyelocytic leukemia and beyond |
|
https://doi.org/10.18632/oncotarget.1244
|
| 1128-1129 |
Reviews
|
| Understanding the role of NRF2regulated miRNAs in human malignancies |
|
https://doi.org/10.18632/oncotarget.1181
|
| 1130-1142 |
Research Papers
|
| Radiation therapy induces the DNA damage response in peripheral blood |
|
https://doi.org/10.18632/oncotarget.1084
|
| 1143-1148 |
|
| Gli1 Transcriptional Activity is Negatively Regulated by AKT2 in Neuroblastoma |
|
https://doi.org/10.18632/oncotarget.1074
|
| 1149-1157 |
|
| Targeting mixed lineage kinases in ERpositive breast cancer cells leads to G2/M cell cycle arrest and apoptosis |
|
https://doi.org/10.18632/oncotarget.1093
|
| 1158-1171 |
|
| Identification of pregnancyassociated plasma protein A as a migrationpromoting gene in malignant pleural mesothelioma cells: a potential therapeutic target |
|
https://doi.org/10.18632/oncotarget.1126
|
| 1172-1184 |
|
| Combining TRAIL with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling |
|
https://doi.org/10.18632/oncotarget.1162
|
| 1185-1198 |
|
| Annexin A2 is regulated by ovarian cancerperitoneal cell interactions and promotes metastasis |
|
https://doi.org/10.18632/oncotarget.1122
|
| 1199-1211 |
|
| Small MoleculeInduced Mitochondrial Disruption Directs Prostate Cancer Inhibition via Unfolded Protein Response Signaling |
|
https://doi.org/10.18632/oncotarget.1130
|
| 1212-1229 |
|
| Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival |
|
https://doi.org/10.18632/oncotarget.1145
|
| 1230-1240 |
|
| A novel Mcl1 variant inhibits apoptosis via increased Bim sequestration |
|
https://doi.org/10.18632/oncotarget.1147
|
| 1241-1252 |
|
| Combination therapy with antiErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Nonsmall Cell Lung Cancer |
|
https://doi.org/10.18632/oncotarget.1141
|
| 1253-1265 |
|
| PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1 |
|
https://doi.org/10.18632/oncotarget.1164
|
| 1266-1279 |
|
| Critical role of zinc finger protein 521 in the control of growth clonogenicity and tumorigenic potential of medulloblastoma cells |
|
https://doi.org/10.18632/oncotarget.1176
|
| 1280-1292 |
|
| HMGA1 promotes metastatic processes in basallike breast cancer regulating EMT and stemness |
|
https://doi.org/10.18632/oncotarget.1136
|
| 1293-1308 |
Research Perspectives
|
| Cancer Metabolism: New Validated Targets for Drug Discovery |
|
https://doi.org/10.18632/oncotarget.1182
|
| 1309-1316 |
|
| A Tumor initiating cellenriched prognostic signature for HER2+:ERα breast cancer; rationale new features controversies and future directions |
|
https://doi.org/10.18632/oncotarget.1170
|
| 1317-1328 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß